MLYS Chief Commercial Officer Eric Warren Sells 104,124 Shares

Eric Warren, the Chief Commercial Officer of Mineralys Therapeutics, Inc. (NasdaqGS: MLYS), sold 104,124 shares on June 26, 2026. The transaction was valued at approximately $2.7 million, with an average price of $25.9 per share. This sale was conducted under a planned trading program.

Insider Buying and Selling at Mineralys Therapeutics, Inc.

Eric Warren's recent transaction was part of a planned sale, involving 104,124 shares at an average price of $25.9. On the same day, Warren also bought 104,124 shares at a price of $13.24, indicating strategic trading activity. Additionally, Jon Congleton, the CEO, sold 75,000 shares on June 30, 2026, as part of a planned sale.

Other Institutional Activity in Mineralys Therapeutics

Wellington Management Group made a notable move by increasing its position in Mineralys Therapeutics by 2,574,801 shares, marking a 328.3% increase. It now holds 3,359,068 shares worth about $90.9 million. Meanwhile, RA Capital Management added 369,000 shares, boosting its stake by 5% to 7,692,750 shares valued at $208.4 million. BlackRock, Inc. also increased its stake by 153,904 shares, a 3.6% rise, to hold 4,481,582 shares valued at $121.4 million.

Mineralys Therapeutics, Inc. Stock Down 3.7%

On Wednesday, shares of Mineralys Therapeutics (NasdaqGS: MLYS) traded near $26.88. The company has a market capitalization of approximately $2.35 billion and a forward P/E ratio of -12.73, reflecting its non-profitable status. The stock's 52-week range spans from $12.59 to $47.65, with a 50-day moving average of $27.42 and a 200-day moving average of $32.88. Mineralys maintains a strong liquidity position with a current ratio of 44.33 and a quick ratio of 43.90.

Analysts Set New Price Targets

Several analysts have maintained their bullish outlook on Mineralys Therapeutics. On March 13, 2026, B of A Securities reiterated its 'buy' rating with a price target of $51. Other firms like Stifel, HC Wainwright & Co., and Wells Fargo have also maintained 'buy' ratings with targets ranging between $50 and $56. The consensus among eight analysts is a 'strong buy,' with a mean price target of $49.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc. is a biopharmaceutical company based in Radnor, Pennsylvania. It focuses on developing treatments for diseases driven by dysregulated aldosterone. Its lead product, lorundrostat, is an orally administered inhibitor targeting conditions like hypertension and chronic kidney disease. Founded in 2019, the company is led by CEO Dr. Jon Congleton and employs 76 people.

Bottom Line

Eric Warren's recent share sale at Mineralys Therapeutics is part of planned insider trading activity. Investors often track these transactions for potential insights, though they don't necessarily indicate future stock performance. It's important to remember that insider sales can be for various reasons unrelated to the company's prospects.